Longboard Pharmaceuticals CEO Kevin Lind's 2023 pay jumps 36% to $2.1M
Longboard Pharmaceuticals reports 2023 executive compensation
By ExecPay News
Published: April 12, 2024
Longboard Pharmaceuticals reported fiscal year 2023 executive compensation information on April 12, 2024.
In 2023, three executives at Longboard Pharmaceuticals received on average a compensation package of $1.4M, a 13% increase compared to previous year.
Average pay of disclosed executives at Longboard Pharmaceuticals
Kevin R. Lind, Chief Executive Officer, received $2.1M in total, which increased by 36% compared to 2022. 48% of Lind's compensation, or $987K, was in option awards. Lind also received $443K in non-equity incentive plan, $610K in salary, as well as $14K in other compensation.
Randall E. Kaye, Chief Medical Officer, received a compensation package of $1.2M, which decreased by 16% compared to previous year. 41% of the compensation package, or $473K, was in salary.
Brandi L. Roberts, Chief Financial Officer, earned $1M in 2023, a 19% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 12, 2024.